Sign in
Anti-VEGF treatment switch in DME and nAMD: a comparison of aflibercept versus ranibizumab after a single-dose switch
Estephania Feria, MD
On Demand Cases, Courses, and Papers
2019
Phase III Randomized Clinical Trial Comparing SB15 With Reference Aflibercept in Neovascular Age-Related Macular Degeneration 56-Week Results
Min Sagong, MD
Annual Meeting Talks
2023
Does Anti-VEGF Therapy Affect the Rate of Expansion of Geographic Atrophy in Patients with Neovascular AMD Managed by a Treat-Extend-Stop Protocol?
Sean David Adrean, MD, FAAO, FASRS
Category: Neovascular AMD